|
WO2021011609A1
|
|
Methods of treating ovarian, fallopian tube and peritoneal cancer
|
|
WO2020225753A2
|
|
Methods for characterizing and treating a cancer type using cancer images
|
|
WO2020072796A1
|
|
Crystalline forms of niraparib freebase
|
|
TW202028181A
|
|
Niraparib salts
|
|
TW202024638A
|
|
Methods of treating cancer
|
|
KR20200118117A
|
|
Niraparip preparations for children and treatment methods for children
|
|
KR20200105862A
|
|
How to treat cancer
|
|
SG11202002499TA
|
|
Combination therapies and uses thereof
|
|
AU2018338901A1
|
|
Combination therapies for treating cancer
|
|
BR112020006039A2
|
|
niraparib formulations
|
|
CA3063715A1
|
|
Combination therapies for treating cancer
|
|
KR20200018436A
|
|
Combination Therapy for Cancer Treatment
|
|
KR20200003843A
|
|
Antibody Agents for Lymphocyte Activation Gene-3 (LAG-3) and Uses thereof
|
|
US2020055837A1
|
|
Methods of manufacturing of niraparib
|
|
WO2018183349A1
|
|
Niraparib formulations
|
|
CN110944638A
|
|
Nilaparib compositions
|
|
WO2018136887A1
|
|
Compounds
|
|
WO2018136437A2
|
|
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
|
|
KR20190098263A
|
|
How to Treat Cancer with Anti-TIM-3 Antibodies
|
|
BR112019014187A2
|
|
Cancer treatment methods with anti-pd-1 antibodies
|
